In this issue:
- Ide-cel or standard regimens in relapsed/refractory multiple myeloma
- Pembrolizumab + AVD for untreated classical Hodgkin lymphoma
- Liso-cel as second-line therapy for large B-cell lymphoma
- Epcoritamab for relapsed/ refractory large B-cell lymphoma
- Response after immunotherapy and SCT for relapsed/refractory ALL with Ph-like fusions
- ICI-associated arrhythmias
- Sugemalimab for relapsed/ refractory ENKTL
- GD2-CART01 for relapsed/ refractory high-risk neuroblastoma
- Risk-stratified, response-adapted regimen for young classical Hodgkin lymphoma
Please login below to download this issue (PDF)